GMAB Genmab
- 30.220
- +0.690+2.34%
- 29.760
- -0.460-1.52%
Genmab News
Genmab Announces Presentation Of Multiple Abstracts On Epcoritamab At 2024 European Hematology Association Congress On June 13-16
Genmab Announces Presentation Of Multiple Abstracts On Epcoritamab At 2024 European Hematology Association Congress On June 13-16
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
Media ReleaseCOPENHAGEN, Denmark; May 14, 2024 Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development programThree oral pres
Watching Genmab; Shares Trading Higher After Novo Nordisk Announced Results From The FRONTIER 2 Trial In People Aged 12 Years Or Older With Haemophilia A
Watching Genmab; Shares Trading Higher After Novo Nordisk Announced Results From The FRONTIER 2 Trial In People Aged 12 Years Or Older With Haemophilia A
Genmab A/S Details Capital and Corporate Structure
6-K: Report of foreign private issuer (related to financial reporting)
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is
Genmab Advances Share Buy-back Program
Transactions in Connection With Share Buy-back Program
Zaiding Pharmaceuticals announced that partners Pfizer and Genmab have jointly announced that the US Food and Drug Administration (FDA) has approved TIVDAK (tisotumab vedotin-tftv)'s supplementary biologics license application (SBLA) to fully approve it f
Zaiding Pharmaceuticals announced that partners Pfizer and Genmab have jointly announced that the US Food and Drug Administration (FDA) has approved TIVDAK (tisotumab vedotin-tftv)'s supplementary biologics license application (SBLA) to fully approve it for the treatment of patients with recurrent or metastatic cervical cancer whose disease progresses during or after chemotherapy.
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Cigna (CI) and Genmab (GMAB)
Genmab (GMAB) Receives a Buy From Truist Financial
Optimistic Outlook for Genmab: Strategic Growth and Product Performance Underpin Buy Rating
Earnings Call Summary | Genmab(GMAB.US) Q1 2024 Earnings Conference
The following is a summary of the Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript:Financial Performance:Genmab reported strong growth across its portfolio in Q1 2024, with notable gain in DARZALEX
Genmab Posts Q1 Net Profit Surge; Revenue Jumps
Genmab (GMAB.CO) said Thursday net profit for the first quarter surged as revenue jumped year over year. Net profit for the three months ended March 31 was 1.33 billion Danish kroner, compared with 21
Genmab (GMAB.US): The 2024 Q1 financial report achieved revenue of US$600.4 million, previous value of US$411.3 million, expected value of US$577.5 million; earnings per share were US$0.29, previous value was US$0.05, and expected value was US$0.14.
Genmab (GMAB.US): The 2024 Q1 financial report achieved revenue of US$600.4 million, previous value of US$411.3 million, expected value of US$577.5 million; earnings per share were US$0.29, previous value was US$0.05, and expected value was US$0.14.
Genmab Reports Q1 Results
Genmab Q1 2024 Revenue $604.25M
Genmab Q1 2024 Revenue $604.25M
Press Release: Genmab Announces Financial Results for the First Quarter of 2024
Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights -- The U.S. Food and Drug
Genmab Q1 2024 Earnings Preview
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer
Pfizer (PFE) and Genmab (GMAB) said Monday that the US Food and Drug Administration approved a supplemental biologics license application for Tivak to treat patients with recurrent or metastatic cervi
Analysis
Price Target
No Data
